Search

everythinglearnresearchcommunity

for

Search:↓

The Brazilian version of the Alopecia Areata Quality of Life Index is reliable for assessing patients' quality of life.

The trial aims to test if spironolactone is an effective acne treatment for women without the side effects of current treatments.

Baseline severity, disease activity, and relapse history are key to predicting response and recurrence in alopecia areata.

Higher inflammation markers are linked to more severe alopecia areata.

Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.

Pityriasis rubra pilaris significantly worsens quality of life more than many other health conditions.

There is a significant need for better-validated quality of life tools in dermatology.

Baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata.

Lower GPX4 mRNA levels are linked to higher disease activity and symptoms in lupus patients.

Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.

The Spanish Hair-Specific Skindex-29 questionnaire effectively measures the quality of life impact of hair loss in Spanish-speaking women.

Amputation stump skin disease worsens life quality, especially in men during summer, and long prosthesis use increases fungal infection risk.

The DLQI is a key tool for measuring quality of life in dermatology.

Tofacitinib effectively and safely promotes hair regrowth in alopecia patients.

Inherited ichthyosis negatively impacts quality of life, affecting daily activities, self-image, and reproductive decisions.

Experts agreed on guidelines to improve research on Frontal Fibrosing Alopecia.

Low-dose tofacitinib is effective and cheaper for severe alopecia areata.

Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.

Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.

Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.

Tofacitinib helps hair regrow in some kids with severe alopecia areata, but more research is needed on long-term effects.

Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.

Quality of life, overall survival, and progression-free survival should be equally prioritized in advanced breast cancer treatment decisions.

Patients with certain baseline characteristics are more likely to benefit early from baricitinib for alopecia areata.

People with psoriasis have more health problems, including autoimmune diseases, than those without it.

The STRIAA tool helps doctors quickly and effectively assess the severity of Alopecia Areata.

The dense fine speckled pattern in ANA tests is common in autoimmune diseases, challenging previous beliefs that it was unrelated.

Improving diet may help manage sleep disorders.

BAFF-targeted therapies can reduce autoimmune disease activity, but more research is needed for precise treatments.

The C-CAT tool helps assess and improve treatment for central centrifugal cicatricial alopecia.